Prof. Ashraf Zedan Abdallah

Education:

M.B.B.Ch:                     Assiut Faculty of Medicine, September 1982

M.S (Oncology):            Dept. of Radiation Oncology, Assiut University,1987

M.D (Oncology):            Dept. of Radiation Oncology, Assiut university, 1993

Present post:

   Head of Medical Oncology Dept., South Egypt Cancer Institute, 17 September 2003 till now.

Posts held:

·        House Officer, Assiut University Hospital, 1 March 1983

·        Resident, Dept. of Radiation Oncology, Assiut University Hospital, 1 March 1984

·        Demonstrator, Dept. of Radiation Oncology, Assiut University, 21 May 1987

·        Assistant Lecturer, Dept. of Radiation Oncology, Assiut University, 7 February 1988

·        Lecturer, Dept. of Radiation Oncology, Assiut University, 30 June 1993

·        Assistant Professor of Clinical Oncology, Faculty of Medicine, Assiut University, 26 July 1998

·        Supervisor of Medical Oncology Dept. South Egypt Cancer Institute, 26 July 1999

·        Head of Medical Oncology Dept. South Egypt Cancer Institute, 17 September 2003

·         Professor of Clinical Oncology, Faculty of Medicine, Assiut University, 25 July 2004

Scientific Associations Membership:

-         American Society of Clinical Oncology (ASCO)

-         European Society of therapeutic Radiology and Oncology (ESTRO)

-         International Society of Pediatric Oncology (SIOP)

-         Pan Arab Oncology Association

-         Egyptian Society of Cancer

-         Egyptian Group of Pediatric Oncology

Publications:

·        Mahfouz  HA, Zedan A, Abd Elrazik MA, Abdalla AA: Concomitant boost accelerated radiation therapy for advanced squamous cell carcinoma of the larynx and hypopharynx. Assiut Med. J. 1997; 3(21).

·        Asber RA, Zedan A: Differentiation between malignant and benign breast lesions using Technetium-99m Sestamibi. Egyptian N.C.I. J. 1996; 2(8).

·        Zedan a, Gaber MS, Ali AS, Mohammed SI: Feasibility of accelerated fractionation radiation, concurrent with 5-Fluorouracil (5-FU) and Cisplatin (CDDP) for locally advanced esophageal cancer. Assiut Med. J. 1997; 3(21).

·        Zedan A: the role of Radioiodine and Technetium-99m Sestamibi in the evaluation of patients with differentiated Thyroid cancer after surgery. El- Minia Med. Bull. 1997; 1(8).

·        Zedan A, Abdalla AA: Tamoxafin in patients with advanced epithelial ovarian carcinoma. . El- Minia Med. Bull. 1996; 2(7).

·        Anwar MM, Zedan A: Prognostic significance of serum laminin P1 in conjunction with PSA in cancer prostate. Arab J. of labora. Medice..1994; 2(10).

·        Gaber MS, Ali SA, Zedan A, Moustafa MM.: Evaluation of the efficacy and toxicity of Florouracil and Leucovorin (5-FU/LV) with pelvic irradiation as adjuvant therapy for patients with resected rectal cancer. Egyptian GIT J. 1997; 1(7).

·        Gaber MS, Zedan A, Makkawy M, Abdalla AA, Moustafa MM.:Concomitant adjuvant chemotherapy (Florouracil, Epirubicin and Cyclophosphamide) and post-operative radiotherapy in upper Egyptian patients with respectable T3 and T4 breast carcinoma. Assiut Med. J. 1997; 4(21).

·        Zedan A, Ibrahim MA, Ali FK.: The prognostic value of Interleulin-6 (Il-6) and C-Reactive protein (CRP) in Non- Hodgkin’s Lymphoma  (NHL). Assiut Med. J. 2003; 1(27).

·        Zedan A, Abdalla AA.: Survival and patterns of relapse in colorectal carcinoma. Med. J. of Cairo Univ.2001, 4(4).

·        Zedan A, El-Gammal TA.: Treatment outcome of reconstruction using free vascular fibular transfer with pre& post-operative chemotherapy after resection of lower limb osteosarcoma in children and adolescents. Assiut Med. J. 2003; 1(27).

·        Zedan A, Sayed M.: Evaluation of efficacy and toxicity of 186Re-HEDP in palliation of breast cancer painful bone metastases. El-Minia Med. Bull. 2002; 1(13).

·        Zedan A, Abdul-wahab AA.: Concurrent chemoradiotherapy (CCRT) for Nasopharyngeal carcinoma (NPC). Assiut Med. J. 2002; 1(26).

·        Zedan A, shehata S, Abdel-Raheem M.: Evaluation of single dose versus fractionated palliative radiotherapy in breast cancer painful bone metastases. Med. J. of Cairo Univ. 2001; 1(12).

·        Mostafa EM, Foud E, Zedan A, Abdulla M, Abdel-Salam M.: Cisplatin and Paclitaxel concomitant with radiotherapy in locally recurrent cancer cervix. Med. J. of Cairo Univ. 2002; 1(9).

·        Saleh Y, Zedan A, Al-Osely M, Al-Kateb A, Aly HA, Badawy A.: Local tumor control and cosmetic outcome in breast cancer after immediate reconstruction using T.R.A.M. flap and adjuvant therapy. Egypt. J. Plast. Reconstr. Surg. 2003; 1(27).

·        Fouad E, Mostafa EM, Zedan A.: Adjuvant Cisplatin with concurrent radiation therapy for respectable locally advanced carcinoma of head and neck. Med. J. of Cairo Univ. 2001; 1(12).

·         Meki AM, Gaafar AA, Mustafa KA, Zedan A.: P21 gene, Granulocyte- Macrophage Colony Stimulating Factor, Gelatinases and Carcinoembryonic Antigen Levels In Bilharzial bladder cancer. Arab J. of labora. Medice. 2000; 3(26).

·        Zedan A, Abdalla AA, Mostafa EM, Abdel-Salam M.: Primary Gastroitestinal non-Hodgkin’s Lymphoma (PGI NHL); management and outcome. Med. J. of Cairo Univ. 2001; 4(8).

·        Shehata S, Zedan A, Mahran TZ.: The relation between HER-2/neu expression and response to Vinorelbine/Cisplatin in treatment in treatment of locally advanced and/or metastatic non small-cell lung cancer. Al-Azhar Assiut Med. J. 2003; 1(3).

·        Zedan A, Mahran TZ, Shehata S.: Concurrent chemotherapy with hyperfractionated  radiotherapy in stage III and IV squamous cell head and neck cancer. Al-Azhar Assiut Med. J. 2004; 1(2).

·        Zedan A, Shehata S, Badawy A, Thabet M.: Efficacy of pre-operative chemotherapy and sequential radiation therapy in unresectable rectal carcinoma. Med. J. of Cairo Univ. 2004, 5(29).